CRESIB, Spain

Start : June 2011 | Status : Complete

The scientists: Two scientists are involved in this project: Richard Thomson, PhD and Nuria Antón, PhD. Nuria will spend most of her time in Tres Cantos, while Richard Thomson is dividing his time between Tres Cantos, with Dr. Hernando del Portillo at CRESIB, and the institute FMT-HVD in Manaos, Brazil, which sees around one third of P vivax malaria cases in Manaos and where attempts to establish the culture will be made in collaboration with the group of Dr. Marcus GV Lacerda.

The sponsor: The Barcelona Centre for International Health Research (CRESIB) is a global health research institute developed from some of the leading academic and biomedical research institutions in Barcelona: Universitat de Barcelona, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and the Catalan government.

Foundation funding: The Tres Cantos Open Lab Foundation is providing £267,000 funding for this project.

GlaxoSmithKline’s contribution: GSK has a group working on the P.vivax culture and the CRESIB and GSK scientists will work in close collaboration. This project will require work in the GSK Biosafety level 3 facilities at Tres Cantos.

Project Description: This two-year project is focused on creating a continuous lab-based supply of the P. vivax malaria parasite in the blood stage. If successful this project will offer a technological breakthrough that could facilitate further advances in research on P. vivax and potentially lead to a new era in P.vivax malaria drug discovery. 

"Without GSK’s support, we would not be able to conduct this research. The access to resources at the Tres Cantos facility and expertise of GSK’s scientists are invaluable to helping us achieve our project’s objectives”. (Richard Thomson, Open Lab scientist)